Trials / Conditions / Meningococcal Infection

Meningococcal Infection

22 registered clinical trials studyying Meningococcal Infection — 1 currently recruiting.

Status	Trial	Sponsor	Phase
Active Not Recruiting	Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administere NCT07135986	Sanofi	Phase 3
Completed	Study on a MenACYW Conjugate Vaccine Administered as a Single Dose in Participants Aged 12 Months and Older in NCT06228586	Sanofi Pasteur, a Sanofi Company	Phase 3
Recruiting	Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to Men NCT04843111	Sanofi Pasteur, a Sanofi Company	—
Completed	A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalen NCT02531698	Pfizer	Phase 2
Completed	Immunogenicity and Safety of Menactra® Vaccine in Subjects Aged 9 to 23 Months in India and in the Russian Fed NCT01890759	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose NCT01543087	Pfizer	Phase 3
Completed	Study of Menactra® in Healthy Subjects at 9 Months and Concomitantly With Pentacel® at 15 to 18 Months of Age NCT01659996	Sanofi Pasteur, a Sanofi Company	Phase 4
Completed	Immunogenicity and Safety Study of GSK Biologicals' Meningococcal Conjugate Vaccine When Co-administered With NCT01340898	GlaxoSmithKline	Phase 3
Completed	Study of a Single Dose of Menactra® Vaccine 4-6 Years After Prior Menactra Vaccine NCT01442675	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Post-licensure Safety Surveillance Study of Menactra Vaccine When Administered As a 2-dose Schedule to Childre NCT01689155	Sanofi Pasteur, a Sanofi Company	—
Completed	Study of Two Doses of Menactra® or One Dose of Monovalent Meningococcal Group C Vaccine With Routine Immunizat NCT01359449	Sanofi Pasteur, a Sanofi Company	Phase 3
Completed	A Study of Meningococcal Vaccine, Menactra® in Healthy Subjects in India NCT01086969	Sanofi	Phase 3
Completed	A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers NCT01049035	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Study to Evaluate the Safety of Novartis MenACWY Conjugate Vaccine When Administered With Routine Infant Vacci NCT00806195	Novartis	Phase 3
Completed	Dose Comparison Study of Menactra® in US Children NCT00700635	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Safety and Immunogenicity of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Toddlers NCT00631995	Sanofi Pasteur, a Sanofi Company	Phase 1
Completed	Evaluation of Vaccination Reminder/Recall Systems for Adolescent Patients NCT00715234	University of Colorado, Denver	N/A
Completed	Immunogenicity of the Booster Dose of Two MenC Vaccines NCT00392808	Centro Superior de Investigación en Salud Publica	Phase 4
Completed	Persistence of Antibodies in Children Aged 7 to 15 Years Who Previously Received One Dose of Menactra® or Meno NCT00258856	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Persistence of Antibodies in Adolescents and Adults 15 to 23 Years Who Received One Dose of Menactra® or Menom NCT00269477	Sanofi Pasteur, a Sanofi Company	Phase 2
Completed	Safety, Tolerability and Immunogenicity of Meningococcal C Conjugate Vaccine to Children 32 to 40 Months of Ag NCT00310635	Novartis	Phase 4
Completed	Study of a Tetravalent Meningococcal Diphtheria Toxoid Conjugate Vaccine in Toddlers 9 to 18 Months of Age NCT00643916	Sanofi Pasteur, a Sanofi Company	Phase 2